Janssen Biotech Secures Another DART Molecule in US$740 M Deal with MacroGenics
By Jawala Prasad & Heather Cartwright
Pharma Deals Review: Vol 2016 Issue 6 (Table of Contents)
Published: 11 Jun-2016
DOI: 10.3833/pdr.v2016.i6.2166 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Johnson & Johnson’s Janssen Biotech has expanded its collaboration with MacroGenics, paying US$75 M upfront to license global rights to MGD015, a preclinical bispecific antibody targeting CD3 and an undisclosed tumour antigen that is being developed for the potential treatment of haematological malignancies and solid tumours...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS